Innovation Pharmaceuticals
MA - Wakefield
Pharmaceutical2 H-1B visas (FY2023)Focus: Small Molecules
Innovation Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (2)
GOZELLIX
gozetotide
Growth
PeptideINTRAVENOUS · POWDER
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows positron emission tomography.
prostate cancer
2025
0
LASIX ONYU
furosemide
Launch
SUBCUTANEOUS · SOLUTION
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone. 12.2 Pharmacodynamics In patients with NYHA Class II and Class III heart failure, subcutaneous administration of Lasix ONYU (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, total 80 mg furosemide within 5 hours) produced similar diuresis and natriuresis to intravenous administration (single 80 mg bolus) at 8- and 24-hour post-dose. The duration of diuretic effect with Lasix ONYU is at least 8 hours after initiation of dosing. 12.3 Pharmacokinetics Absorption In patients with NYHA Class II and Class III heart failure, subcutaneous infusion of Lasix ONYU (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, 80 mg furosemide total), the bioavailability was 112% (90% CI: 104, 120%), with a median Tmax of 5 hours relative to 80 mg intravenous furosemide (single 80 mg bolus). The pharmacokinetic parameters of Lasix ONYU are presented in Table 3 below: Table 3: Pharmacokinetic Data of Lasix ONYU Following Subcutaneous Infusion (n = 18) Dose C max (ng/mL) Mean ± SD AUC t (ng×hr/mL) T 1/2 (hr) AUC ∞ (ng×hr/mL) Lasix ONYU: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) 2010 ± 391 13000 ± 2510 3.7 ± 0.7 13100 ± 2550 Furosemide administered as single 80 mg bolus dose intravenously 13800 ± 4100 11900 ± 3380 3.7 ± 1.3 12000 ± 3400 The terminal half-life of furosemide is approximately 2 hours. The impact of subcutaneous edema at the administration site of Lasix ONYU on drug absorption is unknown. Distribution Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 mcg per mL to 400 mcg per mL are 91% to 99% bound in healthy individuals. The unbound fraction averages 2.3% to 4.1% at therapeutic concentrations. Furosemide binding to albumin may be reduced in elderly patients. Elimination Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is significantly less than in younger healthy male subjects (20 to 35 years of age). Metabolism Furosemide glucuronide is the only or at least the major biotransformation product of furosemide in humans.
edema in adult patients with chronic heart failure
2025
30
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 2 approved products, 2 clinical trials
Top TAs: Cardiovascular, Oncology
H-1B (2023): 2 approvals
Portfolio Health
Launch1 (50%)
Growth1 (50%)
2 total products
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub